AR097553A1 - Derivados de triazolo[4,5-d]pirimidina - Google Patents
Derivados de triazolo[4,5-d]pirimidinaInfo
- Publication number
- AR097553A1 AR097553A1 ARP140103305A ARP140103305A AR097553A1 AR 097553 A1 AR097553 A1 AR 097553A1 AR P140103305 A ARP140103305 A AR P140103305A AR P140103305 A ARP140103305 A AR P140103305A AR 097553 A1 AR097553 A1 AR 097553A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- alkylsulfonyl
- proviso
- cycloalkyl
- Prior art date
Links
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 alquiloxetanilamino Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- MQIWLOJWEIUDPA-LBPRGKRZSA-N (3s)-1-[3-[(4-methoxyphenyl)methyl]-5-(2,2,2-trifluoroethoxy)triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound C1=CC(OC)=CC=C1CN1C2=NC(OCC(F)(F)F)=NC(N3C[C@@H](O)CC3)=C2N=N1 MQIWLOJWEIUDPA-LBPRGKRZSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004439 haloalkylsulfanyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos útiles en el tratamiento de enfermedades del SNC, metabólicas (diabetes), pulmonares, cardiacas, trastornos oculares (retinopatía diabética, glaucoma), inflamación. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R¹ es haloalquilo, halofenilo, alcoxifenilo, alquil-1,2,5-oxadiazolilo, haloalquilfenilo, alquilsulfonilfenilo, halo-piridinilo o alquiltetrazolilo; R² es cicloalquilo, isopropilo, alquenilo, piperidinilo, alquilamino, azetidinilo, pirrolidinilo, cicloalquilamino, alquiloxetanilamino, morfolinilo, (cicloalquil)(alquil)amino, haloalquiloxi, alcoxi, cicloalquilalcoxi, cicloalquiloxi, oxetaniloxi, alquiloxetanilalquiloxi, alquiniloxi, alcoxi-alcoxi, hidroxialquiloxi, alquilsulfanilo, haloalquil-sulfanilo, alquilsulfonilo, hidroxialquilsulfanilo, hidroxi-alquilsulfonilo o alcoxialquilsulfonilo; R³ y R⁴ se eligen con independencia entre hidrógeno, halógeno, hidroxilo, alquilcarbonilamino y alquilo, con la condición de que R³ y R⁴ no sean ambos hidrógeno al mismo tiempo; y n es el número 1 ó 2; o una sal o éster farmacéuticamente aceptable del mismo; con la condición de que se excluya el (S)-1-[3-(4-metoxi-bencil)-5-(2,2,2-trifluoro-etoxi)-3H-[1,2,3]triazolo[4,5-d]pirimidin-7-il]-pirrolidin-3-ol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13183385 | 2013-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097553A1 true AR097553A1 (es) | 2016-03-23 |
Family
ID=49111076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103305A AR097553A1 (es) | 2013-09-06 | 2014-09-04 | Derivados de triazolo[4,5-d]pirimidina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9593123B2 (es) |
| EP (3) | EP3483163B1 (es) |
| JP (1) | JP6441356B2 (es) |
| KR (3) | KR102349567B1 (es) |
| CN (1) | CN105555788B (es) |
| AR (1) | AR097553A1 (es) |
| AU (1) | AU2014317229B2 (es) |
| CA (1) | CA2915766C (es) |
| CL (1) | CL2016000495A1 (es) |
| CR (1) | CR20160076A (es) |
| DK (2) | DK3041843T3 (es) |
| EA (1) | EA028335B1 (es) |
| ES (2) | ES2714094T3 (es) |
| HR (2) | HRP20190361T1 (es) |
| HU (2) | HUE041760T2 (es) |
| IL (1) | IL243092B (es) |
| LT (2) | LT3483163T (es) |
| MA (1) | MA38826B1 (es) |
| MX (2) | MX367084B (es) |
| MY (1) | MY191628A (es) |
| PE (2) | PE20160691A1 (es) |
| PH (1) | PH12016500250B1 (es) |
| PL (2) | PL3041843T3 (es) |
| PT (2) | PT3483163T (es) |
| RS (2) | RS58390B1 (es) |
| SG (1) | SG11201601714UA (es) |
| SI (2) | SI3041843T1 (es) |
| TR (1) | TR201900662T4 (es) |
| TW (1) | TWI705966B (es) |
| UA (1) | UA116395C2 (es) |
| WO (1) | WO2015032769A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162630A1 (en) * | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
| MX2017005857A (es) | 2014-11-07 | 2017-06-26 | Hoffmann La Roche | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2. |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN109232694A (zh) * | 2015-11-06 | 2019-01-18 | 江苏恒瑞医药股份有限公司 | 制备坎格雷洛中间体的方法 |
| WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| CN115073476A (zh) * | 2016-06-23 | 2022-09-20 | 豪夫迈·罗氏有限公司 | 对2型大麻素受体具有亲和力的[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| EP3475280B1 (en) * | 2016-06-23 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| CN106478639B (zh) * | 2016-09-05 | 2018-09-18 | 郑州大学 | 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用 |
| CN106432247B (zh) * | 2016-09-27 | 2018-06-29 | 郑州大学 | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 |
| CN106432248B (zh) * | 2016-09-27 | 2018-11-27 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN106928296A (zh) * | 2017-02-06 | 2017-07-07 | 上海华升生物科技有限公司 | 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法 |
| CN107033148B (zh) * | 2017-05-03 | 2018-10-26 | 郑州大学 | 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用 |
| CN106928235A (zh) * | 2017-05-03 | 2017-07-07 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN109516990B (zh) * | 2017-09-19 | 2021-06-01 | 天津药物研究院有限公司 | 嘧啶并三氮唑类化合物、其制备方法和用途 |
| CN113582935A (zh) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用 |
| CN115246832B (zh) * | 2022-06-15 | 2024-05-24 | 深圳湾实验室 | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
| CN119912457B (zh) * | 2025-03-03 | 2025-10-10 | 郑州大学 | 嘧啶并三氮唑类化合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514260A (ja) | 1997-09-02 | 2001-09-11 | デュポン ファーマシューティカルズ カンパニー | Ｃｎｓおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類 |
| CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US20060128708A1 (en) * | 2004-06-17 | 2006-06-15 | The Regents Of The University Of California | Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| WO2008141239A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| WO2010120987A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| HUE036244T2 (hu) | 2011-10-27 | 2018-06-28 | Lek Pharmaceuticals | Triazolo-pirimidin vegyületek szintézise |
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
| MX2014015491A (es) | 2012-07-04 | 2015-03-06 | Hoffmann La Roche | Nuevos derivados de adamantilo como agonistas del receptor 2 del canabinoide. |
| CN104837831B (zh) | 2012-12-07 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 新的吡啶衍生物 |
| RS56424B1 (sr) | 2012-12-07 | 2018-01-31 | Hoffmann La Roche | Piridin-2-amidi korisni kao cb2-agonisti |
| US9512141B2 (en) | 2012-12-07 | 2016-12-06 | Hoffmann-La Roche Inc. | Pyrazine derivatives as CB2 receptor agonists |
| CA2885987A1 (en) | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| PE20151539A1 (es) | 2013-03-07 | 2015-10-28 | Hoffmann La Roche | Nuevos derivados de pirazol |
| MX376599B (es) | 2013-05-02 | 2025-03-07 | Hoffmann La Roche | Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2). |
| PL2991988T3 (pl) | 2013-05-02 | 2017-10-31 | Hoffmann La Roche | Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2 |
| MX363458B (es) | 2013-06-11 | 2019-03-25 | Hoffmann La Roche | Nuevos derivados de tetrazolona. |
-
2014
- 2014-09-03 MX MX2016002117A patent/MX367084B/es active IP Right Grant
- 2014-09-03 DK DK14761320.2T patent/DK3041843T3/en active
- 2014-09-03 PT PT182069435T patent/PT3483163T/pt unknown
- 2014-09-03 HU HUE14761320A patent/HUE041760T2/hu unknown
- 2014-09-03 AU AU2014317229A patent/AU2014317229B2/en active Active
- 2014-09-03 RS RS20190264A patent/RS58390B1/sr unknown
- 2014-09-03 MX MX2019009100A patent/MX391724B/es unknown
- 2014-09-03 MY MYPI2016700721A patent/MY191628A/en unknown
- 2014-09-03 EP EP18206943.5A patent/EP3483163B1/en active Active
- 2014-09-03 TR TR2019/00662T patent/TR201900662T4/tr unknown
- 2014-09-03 HU HUE18206943A patent/HUE055201T2/hu unknown
- 2014-09-03 DK DK18206943.5T patent/DK3483163T3/da active
- 2014-09-03 UA UAA201603048A patent/UA116395C2/uk unknown
- 2014-09-03 CA CA2915766A patent/CA2915766C/en active Active
- 2014-09-03 PE PE2015002700A patent/PE20160691A1/es unknown
- 2014-09-03 CN CN201480048593.7A patent/CN105555788B/zh active Active
- 2014-09-03 SI SI201431099T patent/SI3041843T1/sl unknown
- 2014-09-03 KR KR1020167008516A patent/KR102349567B1/ko active Active
- 2014-09-03 EP EP21179163.7A patent/EP3943497A1/en active Pending
- 2014-09-03 KR KR1020227034655A patent/KR20220140651A/ko not_active Ceased
- 2014-09-03 RS RS20211007A patent/RS62234B1/sr unknown
- 2014-09-03 PL PL14761320T patent/PL3041843T3/pl unknown
- 2014-09-03 JP JP2016539509A patent/JP6441356B2/ja active Active
- 2014-09-03 LT LTEP18206943.5T patent/LT3483163T/lt unknown
- 2014-09-03 SI SI201431869T patent/SI3483163T1/sl unknown
- 2014-09-03 HR HRP20190361TT patent/HRP20190361T1/hr unknown
- 2014-09-03 ES ES14761320T patent/ES2714094T3/es active Active
- 2014-09-03 PT PT14761320T patent/PT3041843T/pt unknown
- 2014-09-03 SG SG11201601714UA patent/SG11201601714UA/en unknown
- 2014-09-03 EA EA201690478A patent/EA028335B1/ru not_active IP Right Cessation
- 2014-09-03 KR KR1020217017887A patent/KR102454344B1/ko active Active
- 2014-09-03 PE PE2019001869A patent/PE20191528A1/es unknown
- 2014-09-03 PL PL18206943T patent/PL3483163T3/pl unknown
- 2014-09-03 ES ES18206943T patent/ES2883923T3/es active Active
- 2014-09-03 LT LTEP14761320.2T patent/LT3041843T/lt unknown
- 2014-09-03 WO PCT/EP2014/068640 patent/WO2015032769A1/en not_active Ceased
- 2014-09-03 EP EP14761320.2A patent/EP3041843B1/en active Active
- 2014-09-04 TW TW103130651A patent/TWI705966B/zh active
- 2014-09-04 AR ARP140103305A patent/AR097553A1/es active IP Right Grant
-
2015
- 2015-12-14 IL IL243092A patent/IL243092B/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500250A patent/PH12016500250B1/en unknown
- 2016-02-04 MA MA38826A patent/MA38826B1/fr unknown
- 2016-02-16 CR CR20160076A patent/CR20160076A/es unknown
- 2016-02-23 US US15/050,753 patent/US9593123B2/en active Active
- 2016-03-04 CL CL2016000495A patent/CL2016000495A1/es unknown
-
2021
- 2021-08-16 HR HRP20211322TT patent/HRP20211322T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097553A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| ES2773303T3 (es) | Compuestos de quinolina sustituidos selectivamente | |
| AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| AR076319A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| EP2414369B1 (en) | Imidazo[2,1-b][1,3,4]thiadiazole derivatives | |
| CL2008001933A1 (es) | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. | |
| JP2014527407A5 (es) | ||
| BR112015023267A2 (pt) | composto | |
| AR073898A1 (es) | Compuestos de espiro-oxindol y su uso como agentes terapeuticos. | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| JP2017524022A (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| KR20160002850A (ko) | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 | |
| CA2895404A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
| EA028066B1 (ru) | Терапевтические соединения и связанные с ними способы применения | |
| RU2014108478A (ru) | Клеточная композиция, фармацевтическая композиция, набор и способ лечения дегенеративного заболевания сетчатки глаза (варианты) | |
| WO2013017461A1 (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
| AU2014298959B2 (en) | 1,3-disubstituted cyclopentane derivatives | |
| US20170197976A1 (en) | Mth1 inhibitors for treatment of cancer | |
| JP6392352B2 (ja) | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 | |
| AR102539A1 (es) | Triazolo[4,5-d]pirimidinas | |
| EP2804861A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| EP3140295A1 (en) | Heterocyclyl-butanamide derivatives | |
| EP2032142A2 (en) | Novel compounds | |
| TW201446767A (zh) | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 | |
| CL2012000582A1 (es) | Formas polimorfas de 5-amino-1-(4-(4-clorobenzoil)-3,5-diclorobencil)-1,2,3-triazol-4-carboxamida y de su sal de acido orotico; metodos de preparacion; y uso en el tratamiento de canceres solidos, degeneracion macular, retinopatia, leucemia mieloide cronica y sida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |